Introduction
Despite tremendous advances in medicine from non-invasive imaging to minimally invasive surgical techniques, improvements in pain medicine have been seemingly slow to develop or when introduced, to gain widespread acceptance in our medical practices. At first look, perioperative pain control appears to be dominated by only a few therapeutic agents, namely: local anesthetics, opioid analgesics and / or non-steroidal anti-inflammatory agents -NSAIDS. In spite of this, physicians and other health care providers are expected to effectively manage pain under increasingly difficult clinical circumstances.
We are now facing a growing crisis of global proportions -safely and effectively managing pain in obese patients with sleep apnea.
b. Rates of obesity continue to climb -Going Global !
i. Currently 1/3 of the USA adult population is considered Obese and nearly ¼ of children + adolescents are obese. Estimated that 50% of Adults will be obese by 2030 in the USA (CDC web site: http://www.cdc.gov/obesity/data/trends.html) ii. 
Types of Sleep Apnea -Does it really matter?
Is obesity, per se, the primary factor for hypoxia -with or without OSA? Morbidly obese patients experience multiple episodes of post -operative desaturation despite supplemental oxygen. (Ahmad, S. et al. Anesth. Analg. 2008; 138-43.) a. Obstructive Sleep Apnea (OSA)
Risk Factors: Obesity, Thick / fat neck, Micrognathia, Large tongue, Enlarged tonsils, Nasal obstruction i. Patients studied for evidence of airway obstruction found a reduction in the pharyngeal area and that fat deposition had occurred within these tissues. (Horner et all, Eur Respire J. 613-622, 1989) (Thorax 1992; 47:101-105) .
Under restorative sleep, a relaxation of the pharyngeal musculature occurs that will lead to obstruction. Normally, a series of mini arousal events activate the pharyngeal muscles that open the airways. -"snorting" noises. (Lofsky et al, Anesthesia Patient Safety Foundation Newsletter Summer 2002; 12:24-25.) b. Central Sleep Apnea i. Acute and Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.
(Farney RJ. et al, Chest. 2003; 123; 632-639) (Wang D, et al Chest. 2005; 128:1348 -1356 (Walker JM, J Clin Sleep Med. 2007; 3: 455-461.) (Teichtahl H. et al , Expert Opin Drug Saf. 2007; 6; 641-6) (Mogri M. et al, Chest. 2008; 133; 1484 -1488 (Postgrad Med. 2011; 123; 80-7.) (Bohnert AS et al.. JAMA. 2011; 305,1315 -1321 ii. iv. Prevalence of OSA in another hospital population is at least Frey et al, Obes Surg 2003; 13,678-683) .
How to make a difficult situation (a lot) worse -OPIOIDS a. The growing tide of prescription opioid associated deaths
i. In 1997, the American Academy of Pain Medicine and the American Pain Society issued a consensus statement that advocated liberalization of opioids for chronic pain management. Since the statement was published, the use of methadone and oxycodone has increased by 824% and 660%, respectively.
ii. In the United States, the most common non-illicit drug poisonings resulting in death are those related to the use of prescribed opioids, and their incidence has increased over the past decade.
b. Risk factors for Perioperative Respiratory Depression
i. Seventy-seven percent of morbidity due to opioids occurs in the first postoperative day. (Taylor S, et al. Am J Surg. 2005; 190) Additional risks: iii. Patients on chronic opiate therapy for chronic pain have an extremely high prevalence of sleep apnea and nocturnal hypoxemia. Hypoxemia can occur during quiet wakefulness in patients on chronic opioid medications with and without sleep apnea. (Sleep Breath. 2009; 13:49-57) (Mogri M, et al., Anesthesia Patient Safety Foundation Newsletter Summer 2002, 12: 24-25) ii. In one series, twenty-one percent of obese patients used narcotic analgesics for pain.
( Raebel MA et al; Arch Intern Med 2004; 164: 2135-40) iii. There is significant variability in opioid-induced antinociception in the morbidly obese after surgery with up to 10-fold variation observed in opioid requirements not related to body surface area, sex, age, dose per injection or anesthetic agent. (Bennett R. et al., Pharmacotherapy 1982; 2: 50-3) iv. Little is known about the consequences of bariatric surgery on intestinal absorption of drugs, especially that of morphine. In the setting of PCA opioids, PCA might be safe for an individual post bariatric surgical patients when a number of criteria are met that includes dosing on "ideal body weight", essentially reducing the opioid dose by at least one half. (Anesthesiology. 2004; 101:603-13) v. In a PACU based study over a period of nearly 3 years, obesity was significantly associated with a larger number of critical respiratory events than in non-obese subjects.
Although there is no convincing study that has shown a clinical advantage of one opioid (morphine, hydromorphone, fentanyl) over another in the treatment of acute post operative pain (Hill HF. Et al, Anesth Analg 1991; 72:330-6) , Hydromorphone been increasing use of hydromorphone to manage acute post operative pain in the opioid naïve patient. This goes against its historical use in opioid tolerant patients, cancer pain patients and those who cannot tolerate morphine or cannot achieve adequate analgesia with morphine. In fact, the concentrated form of hydromorphone (10mg/cc) was approved for use only in opioid tolerant patients (FDA product insert).
The author has a growing perception that indiscriminant use of hydromorphone and/or other opioids can lead to untoward and/or life threatening respiratory events. Such a view is gaining strength based on an informal review of National patient safety web based -bulletins such as:
-The Pennsylvania Patient Safety Web Advisory -2011, who have focused on the realization that does equivalencies may be wrong or misleading.
-The Anesthesia Patient Safety Foundation notes that the risk of serious injury from PCA in the postoperative period includes a low, unpredictable incidence of life threatening, opioid-induced respiratory depression (RD) in young, healthy patients. Respiratory depression based on bradypnea was many orders of magnitude greater than the 1 to 2 percent widely reported in the literature. MEDMARX and U.S. Pharmacopeia (USP) data show that when PCA pumps are involved, the chance for patient harm increases more than 3.5 times (APSF).
ASA Closed Claims Studies:
.. "Identified 13 additional acute pain management cases found in respiratory or cardiac arrest, but no preceding signs of respiratory depression were noted. On-site reviewers judged that better use of monitoring devices (particularly pulse oximetry or capnography) may have prevented the complication in .. 63 percent of PCA/other claims"
The claims review found poor outcomes (death and brain damage), particularly in the PCA group.. Interestingly, obesity was a factor noted in a number of our respiratory depression claims, consistent with an increased risk of opioid-induced respiratory depression in the obese patient with obstructive sleep apnea. -Case Series: "Three of the four deaths occurred within the first 24 hours postoperatively ..and three of the four deaths occurred between midnight and 6 AM. Five of the 32 events occurred in the PACU and the rest (27) occurred on general surgical floors." ..many of the events occurred at relatively modest opioid dosages and when pain levels were still significant. That suggested that some might have an increased opioid sensitivity. ..the authors speculated about the potential role of obstructive sleep apnea (OSA) in many patients. Two of the deaths occurred in patients with known OSA. The association with acute renal failure also suggested reduced opioid clearance or global organ dysfunction as contributing factors." (Ramachandran SK, et al. J Clin Anesth 2011; 23: 207-213) Although not focused on the obese patient population, inter-patient differences in opioid mediated analgesia and/or side effects can be and have been documented. This has been a particular issue in determining equipotent dosing between morphine and hydromorphone in opioid naive patients, where conversion ratios of 5:1 to 8:1 have been published. For example, morphine 10mg iv would then be considered to be equivalent to either 1.3mg or 2 mg of iv hydromorphone -a significant difference. Moreover, most providers would be very hesitant to give a post operative patient 10mg of Morphine as a single iv push, yet they appear much more willing to prescribe a dose greater or equal to 1 mg of iv hydromorphone in a single dose. Therefore, although there are no systematic difference between morphine and hydromorphone in opioid-related side effects (Hong D et al, Anesth Analg. 2008; 107:1384-9) , on closer inspection, unique aspects of hydromorphone must be taken into account in opioid naïve patients. If we add the additional complexities of a provider's experience prescribing hydromorphone under conditions of morbid obesity, concurrent renal and/or liver failure, the clinical outcome could be disastrous.
Importantly, the pharmacokinetics of hydromorphone are affected by renal impairment where there is a 2 fold increase in plasma levels in patients with moderate renal impairment (CLcr = 40 -60 mL/min) where as there is a 4 -fold increase with severe renal impairment (CLcr < 30 mL/min). In addition, hydromorphone appears to be more slowly eliminated under conditions of renal failure with a longer terminal elimination halflife (40 hr) compared to patients with normal renal function (15 hr). Therefore, it is recommended that patients with renal impairments a started one-fourth to one-half the usual starting dose. Patients with renal impairment should also be closely monitored during dose titration (FDA product insert).
e. Perioperative OSA protocols -Do they help? (Bolden: et al., Anesth Analg 2007; 105:1868-193) (Gali et al., J. CLin Sleep Med. 2007; 3:582-588) (Gali et al Anesthesiology 2009,110 (4) 869-877) .
ii. Several treatment strategies: Different noninvasive positive airway pressure devices, including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BPAP) therapy, and adaptive servo-ventilation (ASV) have been tried to treat opioid-associated SDB, with conflicting results. Overall, the limited evidence shows that BPAP with a back-up rate may be reasonable treatment to consider in patients with sleep apnea related to long-term opioid use (Gallagher et al., J Surgical 
